277 related articles for article (PubMed ID: 27942241)
1. Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B.
Djambas Khayat C
J Blood Med; 2016; 7():275-282. PubMed ID: 27942241
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
[TBL] [Abstract][Full Text] [Related]
3. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
Korth-Bradley JM; Rendo P; Smith L; Altisent C
Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
[TBL] [Abstract][Full Text] [Related]
5. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
Carcao M; Zak M; Abdul Karim F; Hanabusa H; Kearney S; Lu MY; Persson P; Rangarajan S; Santagostino E
J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
[TBL] [Abstract][Full Text] [Related]
6. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects.
Valentino LA; Rusen L; Elezovic I; Smith LM; Korth-Bradley JM; Rendo P
Haemophilia; 2014 May; 20(3):398-406. PubMed ID: 24418368
[TBL] [Abstract][Full Text] [Related]
7. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Stobart K; Iorio A; Wu JK
Cochrane Database Syst Rev; 2006 Apr; (2):CD003429. PubMed ID: 16625581
[TBL] [Abstract][Full Text] [Related]
8. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Stobart K; Iorio A; Wu JK
Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
[TBL] [Abstract][Full Text] [Related]
9. Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis.
Tardy B; Lambert T; Chamouni P; Montmartin A; Trossaert M; Claeyssens S; Berger C; Ardillon L; Gay V; Delavenne X; Harroche A; Chelle P
Haemophilia; 2022 Jul; 28(4):542-547. PubMed ID: 35420242
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
[TBL] [Abstract][Full Text] [Related]
12. Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX-Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective-Prospective Study.
Coppola A; Rivolta GF; Quintavalle G; Matichecchia A; Riccardi F; Rossi R; Benegiamo A; Ranalli P; Coluccio V; Tagliaferri A
J Clin Med; 2024 Mar; 13(5):. PubMed ID: 38592343
[No Abstract] [Full Text] [Related]
13. First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China.
Yang R; Wu R; Sun J; Sun F; Rupon J; Huard F; Korth-Bradley JM; Xu L; Luo B; Liu YC; Rendo P
Medicine (Baltimore); 2021 May; 100(21):e26077. PubMed ID: 34032739
[TBL] [Abstract][Full Text] [Related]
14. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.
Negrier C; Young G; Abdul Karim F; Collins PW; Hanabusa H; Colberg T; Goldman B; Walsh CE;
Haemophilia; 2016 Jul; 22(4):507-13. PubMed ID: 26936227
[TBL] [Abstract][Full Text] [Related]
15. Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series.
Nagao A; Bingo M; Yamaguchi T; Fukutake K
Cureus; 2023 Jan; 15(1):e33573. PubMed ID: 36779089
[TBL] [Abstract][Full Text] [Related]
16. Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes.
Iorio A; MacDonald V; Caillaud A; Luckevich MD; Christoffersen P; Matino D; Keepanasseril A; Iserman E; Germini F; Bentley A; Poon MC
Res Pract Thromb Haemost; 2023 Mar; 7(3):100106. PubMed ID: 37065846
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials.
Mancuso ME; Eriksson D; Falk A; Hakimi Z; Wojciechowski P; Wdowiak M; Klamroth R
J Blood Med; 2023; 14():427-434. PubMed ID: 37534261
[TBL] [Abstract][Full Text] [Related]
18. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
[TBL] [Abstract][Full Text] [Related]
19. GlycoPEGylated recombinant factor IX for hemophilia B in context.
Santagostino E; Mancuso ME
Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
[TBL] [Abstract][Full Text] [Related]
20. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.
Collins PW; Young G; Knobe K; Karim FA; Angchaisuksiri P; Banner C; Gürsel T; Mahlangu J; Matsushita T; Mauser-Bunschoten EP; Oldenburg J; Walsh CE; Negrier C;
Blood; 2014 Dec; 124(26):3880-6. PubMed ID: 25261199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
